Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Liabilities and Shareholders Equity (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Liabilities and Shareholders Equity for 12 consecutive years, with $89.9 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 134.93% to $89.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $247.9 million through Dec 2025, up 36.14% year-over-year, with the annual reading at $89.9 million for FY2025, 134.93% up from the prior year.
  • Liabilities and Shareholders Equity hit $89.9 million in Q4 2025 for vTv Therapeutics, down from $99.5 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $99.5 million in Q3 2025 to a low of $11.0 million in Q4 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $36.4 million across 5 years, with a median of $31.7 million in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 346.13% in 2021 and later crashed 66.85% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $25.5 million in 2021, then surged by 30.48% to $33.2 million in 2022, then plummeted by 66.85% to $11.0 million in 2023, then surged by 247.3% to $38.3 million in 2024, then soared by 134.93% to $89.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for VTVT at $89.9 million in Q4 2025, $99.5 million in Q3 2025, and $26.4 million in Q2 2025.